Skip to Main Content
Skip Nav Destination

HER2-Targeted Therapy Works Even at Very Low HER2 Levels

June 18, 2024

Abstract: New breast cancer trial results show that the HER2-targeting drug trastuzumab deruxtecan is effective even when tumors express very low levels of HER2. Compared with chemotherapy, the drug increased progression-free survival by 5 months in patients with low or very low HER2 levels. However, the drug also increased the rate of severe and fatal side effects.

You do not currently have access to this content.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal